Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
Top Cited Papers
Open Access
- 22 May 2019
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 7 (1) , 134
- https://doi.org/10.1186/s40425-019-0617-x
Abstract
Background Immune checkpoint inhibitors (ICI) produce durable antitumor responses but provoke autoimmune toxicities, including uncommon but potentially devastating neurologic toxicities. The clinical features, including the spectrum, timing, and outcomes, of ICI-induced neurologic toxicities are not well characterized. Methods We performed disproportionality analysis using Vigibase, the World Health Organization pharmacovigilance database, comparing neurologic adverse event (AE) reporting in patients receiving ICIs vs. the full database. Neurologic AEs were classified by group queries using Medical Dictionary for Regulatory Activities, between database inception to September 28, 2018. Associations between ICIs and neurologic AEs were assessed using reporting odds ratios (ROR) and information component (IC). IC compares observed and expected values to find associations between drugs and AEs using disproportionate Bayesian reporting; IC025 (lower end of the IC 95% credibility interval) > 0 is considered statistically significant. Results Among the full database, 18,518,994 AEs were reported, including 48,653 with ICIs. ICIs were associated with higher incidence of myasthenia gravis (0.47% of ICI reports vs. 0.04% of the full database, ROR 16.5 [95% CI 14.5–18.9]; IC025 3.31), encephalitis (0.51% vs. 0.05%, ROR 10.4 [95% CI 9.2–11.8]; IC025 3.15), peripheral neuropathy (1.16% vs. 0.67%, IC025 0.68), and meningitis (0.15% vs. 0.06%, ROR 3.1 [95% CI 2.5–3.9]; IC025 1.01). Myasthenia gravis and encephalitis were associated with anti-PD-1 whereas other neurologic AEs were associated with anti-CTLA-4. Myasthenia gravis was characterized by high fatality rates (~ 20%), early onset (median 29 days), and frequent concurrent myocarditis and myositis; whereas other neurologic AEs had lower fatality rates (6–12%), later onset (median 61–80 days), and were non-overlapping. Conclusions ICIs produce a spectrum of distinct classes of neurologic AEs that can cause significant morbidity and mortality and tend to occur early and with class-specific associations.Keywords
Funding Information
- National Cancer Institute (K23 CA204726)
This publication has 27 references indexed in Scilit:
- Neurological adverse events associated with immune checkpoint inhibitors: Review of the literatureEuropean Journal Of Cancer, 2017
- Fulminant Myocarditis with Combination Immune Checkpoint BlockadeNew England Journal of Medicine, 2016
- Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literatureAnnals of Oncology, 2016
- Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapyEuropean Journal Of Cancer, 2016
- Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic MelanomaJournal of Clinical Oncology, 2015
- Multiple sclerosisJournal of Clinical Investigation, 2012
- Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discoveryStatistical Methods in Medical Research, 2011
- Anti-HERG activity and the risk of drug-induced arrhythmias and sudden deathEuropean Heart Journal, 2005
- The reporting odds ratio and its advantages over the proportional reporting ratioPharmacoepidemiology and Drug Safety, 2004
- A Bayesian neural network method for adverse drug reaction signal generationEuropean Journal of Clinical Pharmacology, 1998